The University of Tokyo,  The Institute of Medical Science, Division for AIDS Vaccine Development
National Institute of Infectious Diseases, AIDS Research Center, Groups 1 and 2
 
 

updated on February 21, 2024



• Takeshi Yoshida reported his work in J. Virol. (2024.2.20)

Yoshida, T., Kasuya, Y., Yamamoto, H., Kawai, G., Hanaki, K.-i, Matano, T., and Masuda, T. HIV-1 RNAs whose transcription initiates from the third deoxyguanosine of GGG tract in the 5' long terminal repeat serve as a dominant genome for efficient provirus DNA formation. J. Virol., 98:e0182523, 2024.


• Hiroshi Ishii made an oral presentation at 12th IAS Conference on HIV Science, Brisbane, Australia, in July., 2023. (2023.7.26)


• Thi Thu Thao Dang reported her work in Microbiol. Spectr. (2023.7.10)

Dang, T. T. T., Anzurez, A., Nakayama-Hosoya, K., Miki, S., Yamashita, K., de Souza, M., Matano, T., and Kawana-Tachikawa, A. Breadth and Durability of SARS-CoV-2-Specific T Cell Responses following Long-Term Recovery from COVID-19. Microbiol. Spectr., 11:e0214323, 2023.


• Midori Nakamura-Hoshi reported her work in Microbiol. Spectr. (2023.6.27)

Nakamura-Hoshi, M., Nomura, T., Nishizawa, M., Hau, T. T. T., Yamamoto, H., Okazaki, M., Ishii, H., Yonemitsu, K., Suzaki, Y., Ami, Y., and Matano, T. HTLV-1 Proliferation after CD8+ Cell Depletion by Monoclonal Anti-CD8 Antibody Administration in Latently HTLV-1-Infected Cynomolgus Macaques. Microbiol. Spectr., 11:e0151823, 2023.


• Hiroshi Ishii reported his work in Biochem. Biophys. Res. Commun. (2023.6.25)

Ishii, H., Jounai, K., Tsuji, R., Ohshio, K., Kaneda, D., Okazaki, M., Harada, S., Fujiwara, D., and Matano, T. Plasmacytoid dendritic cells stimulated with Lactococcus lactis strain Plasma produce soluble factors to suppress SARS-CoV-2 replication. Biochem. Biophys. Res. Commun., 662:26–30, 2023.


• Machiko Otani reported her work in J. Int. AIDS Soc. (2023.5.23)

Otani, M., Shiino, T., Hachiya, A., Gatanaga, H., Watanabe, D., Minami, R., Nishizawa, M., Teshima, T., Yoshida, S., Ito, T., Hayashida, T., Koga, M., Nagashima, M., Sadamasu, K., Kondo, M., Kato, S., Uno, S., Taniguchi, T., Igari, H., Samukawa, S., … Japanese Drug Resistance HIV-1 Surveillance Network. Association of demographics, HCV co-infection, HIV-1 subtypes and genetic clustering with late HIV diagnosis: a retrospective analysis from the Japanese Drug Resistance HIV-1 Surveillance Network. J. Int. AIDS Soc., 26:e26086, 2023.


• The result of a phase I clinical trial using SeV vector (S001) was reported in J. Infect. Dis. (2016.10.17)

Nyombayire, J., Anzala, O., Gazzard, B., Karita, E., Bergin, P., Hayes, P., Kopycinski, J., Omosa-Manyonyi, G., Jackson, A., Bizimana, J., Farah, B., Sayeed, E., Parks, C.L., Inoue, M., Hironaka, T., Hara, H., Shu, T., Matano, T., Dally, L., Barin, B., Park, H., Gilmour, J., Lombardo, A., Excler, J.-L., Fast, P., Laufer, D.S., Cox, J.H., and the S001 Study Team. First-in-human evaluation of the safety and immunogenicity of a replicating intranasally administered Sendai HIV-1 Gag vaccine: induction of potent T-cell or antibody responses in prime-boost regimens. J. Infect. Dis., 215:95-104. 2017.


• GHIT has announced to the award for a project for development of a Dengue vaccine by VLP Therapeutics in collaboration with Nagasaki University and NIID. (2016.10.5)

This international collaborative project by VLP Therapeutics, Nagasaki University and National Institute of Infectious diseases (NIID), supported by Global Health Innovation Technology [GHIT] Fund, is a pre-clinical study to investigate safety and immunogenicity of a virus-like particle (VLP)-based vaccine against Dengue virus infection. 


    GHIT press room     GHIT web site     VLP Therapeutics web site


• The New York-based International AIDS Vaccine Initiative (IAVI) and the Japan-based biotech DNAVEC Corporation announced the start of a Phase I clinical trial of an HIV vaccine candidate using Sendai virus (SeV) vector at three locations, England, Kenya and Rwanda. The SeV vector AIDS vaccine system has been developed by our research group. (2013.4.2)

 

     Information on this project in IAVI Web




>> AIDS Research Center website

 

Matano Research Group

Welcome to Our Lab!

Contact us

AIDS Research Center
National Institute of Infectious Diseases

1-23-1 Toyama, Shinjuku-ku

Tokyo 162-8640, Japan

Department of AIDS Vaccine Development
The Institute of Medical Science

The University of Tokyo

TEL: 03-5285-1111 (ext. 2302) 

FAX: 03-5285-1165